Critical Review: Scinai Immunotherapeutics (NASDAQ:SCNI) & Nuvalent (NASDAQ:NUVL)

Scinai Immunotherapeutics (NASDAQ:SCNI) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation.

Insider & Institutional Ownership

58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 60.9% of Scinai Immunotherapeutics shares are owned by insiders. Comparatively, 5.0% of Nuvalent shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Scinai Immunotherapeutics and Nuvalent’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Nuvalent	N/A	-40.11%	-35.43%

Volatility & Risk

Scinai Immunotherapeutics has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500. Comparatively, Nuvalent has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500.

Valuation & Earnings

This table compares Scinai Immunotherapeutics and Nuvalent”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.31 million	1.45	-$8.31 million	($9.57)	-0.06
Nuvalent	N/A	N/A	-$425.38 million	($6.06)	-16.88

Scinai Immunotherapeutics has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Scinai Immunotherapeutics and Nuvalent, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1	0	0	0	1.00
Nuvalent	1	0	16	0	2.88

Nuvalent has a consensus price target of $137.25, indicating a potential upside of 34.16%. Given Nuvalent’s stronger consensus rating and higher possible upside, analysts clearly believe Nuvalent is more favorable than Scinai Immunotherapeutics.

Summary

Scinai Immunotherapeutics beats Nuvalent on 7 of the 12 factors compared between the two stocks.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

About Nuvalent

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.